Abstract Details

A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea

Stephanie N. Taylor, MD1, Jeanne Marrazzo, MD, MPH2, Byron Batteiger, MD3, Ned Hook III, MD4, Arlene C. Sena, MD, MPH5, Michael Wierzbicki, PhD6, Hannah Kwak, BS7, Shacondra Johnson, BSPH8, Kenneth Lawrence, PharmD9 and John Mueller, PhD9, 1Section of Infectious Diseases, Louisiana State University Health Sciences Center, New Orleans, LA, 2Division of Infectious Diseases, University of Alabama Birmingham, Birmingham, AL, 3Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, 4Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, 5Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, 6Biostatistics, EMMES Corporation, Rockville, MD, 7Biostatistics, Emmes Corporation, Rockville, MD, 8FHI 360, Durham, NC, 9Clinical Development, Entasis Therapeutics, Waltham, MA